Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com Is Abbott's January Pullback a Good Time to Buy? By Thomas Hughes. Publication Date: 1/24/2026. 
Key Points - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback has made the stock look attractively valued. The move—driven more by market angst than by company-specific weakness—appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
A widely followed Wall Street analyst is highlighting AES Corp (AES) as a stock to watch right now, based on signals from his proprietary Power Gauge system. The model tracks factors like momentum, financial strength, and institutional activity across thousands of U.S. stocks.
He breaks down the full reasoning in a short briefing, including why AES is showing unusual strength at this stage of the market. See the full analysis here This buy zone aligns with price action from 2022–2024, when Abbott was recovering from the post-COVID revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates While some metrics in Abbott's Q4 results and guidance missed expectations, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth underperformed by several hundred basis points, but margin strength helped offset that shortfall. Adjusted earnings per share (EPS) rose about 12% and came in slightly above consensus. By segment, the results underscore Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition fell nearly 9%—but growth in Established Pharmaceuticals and Med Tech largely offset those declines. Established Pharmaceuticals grew roughly 9%, aided by generics and emerging markets, while Med Tech expanded about 12.3% with broad strength across its sub-segments. Margins were generally healthy, though some measures missed certain analyst forecasts. A favorable product mix, strength in Med Tech, reduced COVID-19-related sales and operational improvements still left margins in a solid position. Management expects earnings to grow another ~10% in 2026, outpacing revenue growth and supporting the company's capital-return plans. Abbott's capital returns are a central part of the investment case. As a Dividend King, Abbott has increased its payout annually for more than 50 years and appears positioned to continue doing so. After the pullback the stock yields about 2.5%, and the payout ratio is below 50% of consensus EPS, leaving room for share buybacks—another important tool that helps offset the impact of dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or price-target changes the morning of the release. The consensus view is that this fundamentally healthy company can continue returning capital while reinvesting in growth, and that the growth runway remains meaningful. The MarketBeat consensus share-price target suggests the stock could rebound as much as 30%, potentially reaching new all-time highs, while even the low-end targets imply some upside. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and targeted acquisitions. The planned acquisition of Exact Sciences is one example of how Abbott is expanding its revenue and profit streams as well as its product pipeline. The recent decline has been steep and could extend further, but institutions that bought throughout 2025 are likely to be buyers at these discounted levels. There is tentative support in the $105–$110 range, though it is not yet confirmed. The risk is that ABT shares could fall to the low end of the buy zone before rebounding, potentially testing the $95 level or lower.
| 
